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Abstract
Kidney diseases in human immunodeﬁciency virus (HIV)-infected patients are often misdiagnosed. Despite reductions in
morbidity and mortality owing to widespread use of highly effective combination antiretroviral therapy (cART), acute kidney
injury (AKI) and chronic kidney disease (CKD) are still more common in these patients than in the general population, and are
associated with poor health outcomes. HIV-associated nephropathy and HIV immune complex kidney diseases are the more
recognizableHIV-related kidneydiseases.However, a broad spectrumof kidneydisorders related or not directly relatedwithHIV
infection can be observed, including cART-induced AKI, CKD, proximal tubular dysfunction, crystalluria and urolithiasis,
among others. This review summarizes themajor epidemiologic studies of kidney diseases in HIV-infected patients, discusses
novel approaches that may potentially limit nephrotoxicity such as the use of tenofovir alafenamide, and outlines current
screeningmeasures for early diagnosis of kidney dysfunction or tubular damage, and for accurate detection of increased risk for
acute or chronic kidney diseases.
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Introduction
Human immunodeﬁciency virus (HIV) infection is the infectious
disease of our time. The 2015 UNAIDS report estimates that 36.9
million people are infected and 2 million new cases are detected
yearly [1]. In little more than two decades combination antiretro-
viral therapy (cART) has dramatically changed the HIV reality,
from a fatal disease to a chronic controlled condition, improving
survival and allowing patients to lead long productive lives [2].
Despite this, HIV infection was a leading cause of death world-
wide in the past 23 years [3]. In this regard, HIV-infected patients
are still at higher risk for both acute kidney injury (AKI) and
chronic kidney disease (CKD), which are interconnected syn-
dromes responsible for a heavy burden of mortality [4]. However,
key changes have occurred in past 35 years regarding the aeti-
ology of kidney disease, i.e. a decrease in glomerular disease
and an increase of nephrotoxicity, diabetes mellitus and ne-
phroangiosclerosis [5–7]
Kidney disease in HIV-infected patients
The ﬁrst description of severe proteinuriawith a rapid loss of kid-
ney function in HIV-infected patients with advanced acquired
immune deﬁciency syndrome (AIDS) was published in 1984 [8].
The histopathological pattern corresponded to collapsing focal
segmental glomerulosclerosis (FSGS), a condition, later known
as HIV-associated nephropathy (HIVAN), that usually presents
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high-grade proteinuria and rapid progression to end-stage renal
disease (ESRD). Although HIVAN is the best known example of
HIV-associated kidney disease, a large spectrum of kidney syn-
dromes is now known to occur in HIV-infected patients, as out-
lined in Table 1 [9, 10].
HIVAN and HIVICK
Kidney damage in HIVAN results from a variety of mechanisms
including direct viral cell injury and host susceptibility factors
[5]. Viral infection of podocytes and tubular epithelial cells in-
duces dedifferentiation, proliferation and apoptosis. Different
viral gene products are key determinants for these processes
[11]. Inﬁltrating leukocytes express two HIV co-receptors [12],
meaning that HIV also infects inﬁltrating lymphocytes and
macrophages, which release inﬂammatory mediators promoting
further kidney injury. Recent data suggest a genetic host suscep-
tibility to HIVAN [13]. Two recessive variants of the APOL1 gene,
present mainly in Africans, provide protection against Trypanos-
sona brucei rhodesiensis infection, but play a critical role in the de-
velopment of FSGS in response to diverse kidney insults,
conferring susceptibility to HIVAN in the African American popu-
lation [14]. Both HIVAN and HIV immune complex kidney disease
(HIVICK) were observed predominantly in African Americans
[15], although in Europe HIVICK was mainly observed in non-
Africans [16]. The main histologic patterns of glomerulopathy
in Black South Africans were the ‘classic HIVAN’ (27%) and ‘HI-
VICK’ (21%) [17].
Both HIVAN and HIVICK are more frequent in individuals of
African ancestry. Compared with HIVAN, HIVICK patients have
more antiretroviral therapy exposure, lower viral loads, and high-
er CD4 and eGFR [10, 15, 18, 19]. Indeed, HIVICK is far less likely to
progress to ESRD than HIVAN [15].
HIV infection is commonly associated with repeated infec-
tions and polyclonal immunoglobulin expansion, generating a
susceptibility to immune complex formation with subsequent
Table 1. Differential diagnosis of kidney disease in HIV-infected patients [5, 9, 13]
Acute kidney injury
Common HIV non-speciﬁc causes
Opportunistic infectionsa
Kidney hypoperfusion and ischaemia
Acute interstitial nephritis
Rhabdomyolysis
Urinary tract obstruction: blood clots, fungus balls or crystalluriab
HIV-speciﬁc glomerulopathiesa
Drugsb
Chronic kidney disease
HIV-speciﬁc glomerulopathiesa
HIV-associated nephropathy (HIVAN)
HIV immune complex kidney disease (HIVICK)
Immune complex-mediated glomerulonephritis
Post-infectious glomerulonephritis
Immunoglobulin A nephritis
Mixed sclerotic/inﬂammatory disease
Membranous glomerulopathy
Lupus-like disease
Thrombotic microangiopathy
Common HIV non-speciﬁc glomerulopathiesb
HCV-related membranoproliferative glomerulonephritis/cryoglobulinemia
Amyloidosis
Classic FSGS
Diabetic nephropathy
Minimal change disease
Nephroangiosclerosis
Drugsc
Fluid and electrolyte disorders
Disorders of osmolality
Potassium disorders
Acid-based disorders
Antiretroviral nephrotoxicityc
AKI: abacavir, atazanavir, didanosine, indinavir, ritonavir, saquinavir, tenofovir
CKD: abacavir, atazanavir, indinavir, lopinavir, tenofovir
Acute interstitial nephritis: abacavir, atazanavir, indinavir
Fanconi syndrome: tenofovir, didanosine, abacavir
Renal tubular acidosis: lamivudine, stavudine,
Crystalluria, lithiasis: indinavir, atazanavir and (rare): nelﬁnavir, amprenavir
Nephrogenic diabetes insipidus: didanosine, tenofovir
Others
HIV, human immunodeﬁciency virus; HCV, hepatitis virus C; FSGS, focal segmental glomerulosclerosis; AKI, acute kidney injury; CKD, chronic kidney disease.
aLess common since combination antiretroviral therapy (cART) introduction.
bMore common since cART introduction.
cIncluding antiretroviral drugs listed in Antiretroviral nephrotoxicity.
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kidney deposition, giving rise to HIVICK. Viral replication and the
immune responses to viral proteins and other infection-related
antigens are thought to contribute to the spectrum of immune-
mediated glomerulonephritis that encompasses HIVICK [15].
Acute kidney injury in HIV-infected patients
AKI ismore frequent in HIV-infected individuals than in the non-
infected general population [20]. HIV infection is an independent
risk factor for AKI in hospitalized and community-dwelling pa-
tients. The incidence of AKI is variable according to different lit-
erature sources and comparisons are difﬁcult, as most studies
were retrospective and used diverse AKI diagnosis criteria, main-
ly based on clinical judgment [20]. However, incidence of AKI ap-
pears to have decreased with widespread cART use, when AKI is
diagnosed by using the new classiﬁcation criteria [21, 22]. In any
case, AKI remains common.
In the developed world and in the cART era, the incidence of
AKI in ambulatory HIV-infected patients was reported to range
from 2.7 to 6.9 per 100 person-years [21, 23–25]. The incidence dif-
fered between early and late-onset AKI, being more than 10-fold
lower after the initial 3months of HIV care [23]. This suggests that
cART and control of opportunistic infections are associated with
decreased risk of AKI.
Among hospitalized patients AKI occurs at 2–3 times the rate
observed in uninfected controls [20] and the incidence ranges be-
tween 6 and 18% [20, 22, 26]. The highest AKI incidence, as ex-
pected, was observed in intensive care unit settings, ranging
from 47 to 66%. The main risk factors were previous comorbid-
ities such as CKD and illness severity [27, 28].
In general, AKI in HIV-infected individuals is more frequently
related to severe opportunistic infections than to direct cART tox-
icity [20–22, 29].
In the pre-cART era, volume depletion, sepsis and nephrotox-
icity were the leading causes, with 38% of AKI cases being
pre-renal [30]. Vascular or glomerular diseases and drug-induced
microtubular obstruction were common ﬁndings in biopsies
among patients with AKI [30]. In the cART-era, the decrease in op-
portunistic infections and mortality and the increase in non-HIV
comorbidities changed the incidence of AKI [23]. However, the
aetiology remains diverse and mainly multifactorial, with most
of the cases caused by more than two contributing factors [21].
Pre-renal causes such as volume depletion, sepsis and liver dis-
ease remain important factors, especially in severe AKI cases [21].
In different settings nephrotoxicity accounted for up to 30%
of AKI episodes [28]. Medications frequently used to treat
HIV-related infections have been associated with AKI, such as
aminoglycosides, pentamidine, amphotericin and trimetho-
prim/sulfamethoxazole, and antivirals such as acyclovir and fos-
carnet, among others. Roe and colleagues showed that cART
toxicity may account for 14% of late-onset AKI [21], as discussed
in detail below. Nonsteroidal anti-inﬂammatory drugs or iodi-
nated contrastsmayalso cause AKI. Urinary obstruction-induced
AKI is relatively rare and causes include nephrolithiasis and
medication-induced crystalluria [20, 31, 32]. Many other factors
may contribute to the susceptibility for developing AKI in HIV pa-
tients [24, 31, 33–35] and individual antiretroviral drug toxicity is
rarely implicated as the sole cause of AKI [21, 24].
Risk factors for AKI did not differ substantially between the
pre-cART and cART era. Among ambulatory patients, underlying
CKD, AIDS and HCV co-infection aremajor risk factors [21, 23, 24,
29, 36]. In comparison, among hospitalized patients AKI has been
associated with older age, previous CKD, diabetes and also with
HCV co-infection [20, 22]. In a prospective analysis, 35% of HIV/
HCV co-infected individuals developed AKI compared with 17%
of mono-infected HCV subjects, suggesting that HIV-related fac-
tors such as cART could play a more signiﬁcant role in AKI risk
that HCV infection per se [36].
Short- and long-term mortality is increased in AKI-HIV
patients, as shown by a 5-fold increased in-hospital mortality in
those patients [20]. In a Portuguese cohort of 489 HIV hospitalized
patients, mortality was 27.3% in AKI versus 8% for non-AKI pa-
tients [26]. Moreover, long-termmortality is higher inHIV patients
with AKI, the cumulative probability of death at 5 years being
31.3% compared with 16.5% in non-AKI HIV [37]. Recent data
suggest that the incidence of dialysis-requiring AKI among hospi-
talized HIV patients has increased from 0.7 to 1.36% between 2002
and 2010, and severe AKI remains a signiﬁcant predictor of in-
hospital mortality [38]. Additionally, AKI in HIV-infected patients
is associated with a high risk of adverse outcomes beyondmortal-
ity, including heart failure and ESRD [39].
Chronic kidney disease in HIV-infected patients
In the contemporary era of cART, CKD has emerged as a cause of
morbidity and mortality in HIV patients [40]. Both HIV infection
and the adverse effects of cART have been linked to CKD. How-
ever, the global burden of CKD in the HIV population remains dif-
ﬁcult to estimate [5, 16, 41] due to differences in the studied
populations, historic periods, settings, and also in the estimated
glomerular ﬁltration rate (eGFR) equations used [18, 42, 43]. The
reported prevalence of CKD (eGFR <60 mL/min/1.73 m2) among
HIV-infected persons in North America and Europe ranges from
4.7 to 9.7%, but was as high as 33% when deﬁned by either re-
duced GFR or pathological proteinuria [44, 45]. CKD was higher
when combining HIV related with traditional risk factors, such
as diabetes and hypertension [41, 46]. In HIV-infected African po-
pulations the reported prevalence of CKD ranges between 3.5 and
48.5% [47].
Studies in Brazil have reported CKD prevalence rates from 3.8
to 8.4% [48, 49]. In a prospective Portuguese study, the prevalence
of CKD was 5.9% in a cohort of 1281 patients using the creatinine
(SCr)-based Chronic Kidney Disease Epidemiology Collaboration
(CKD-EPI) equation to estimate GFR [50]. In a subsequent assess-
ment of 966 patients from the same cohort, CKD prevalence was
3.9%, 4.4% and 6.1% when assessed by SCr-based CKD-EPI or
Modiﬁcation of Diet in Renal Disease (MDRD) and serum Cystatin
C-based CKD-EPI equations, respectively [51].
In longitudinal studies the reported incidence of kidney func-
tion decline among HIV patients ranges from 3.3 to 11.2 per 1000
person-years [41, 46, 52]. In cross-sectional studies the preva-
lence of declining kidney function ranges from 4% to 17% in dif-
ferent populations [52, 53].
Recently, the EuroSIDA study reported that only 0.64% of 9044
patients developed advanced CKD/ESRD/renal death during a
median follow-up of 5.0 years, with an incidence rate of 1.32
per 1000 person-years follow-up. At 6 years from baseline,
0.83% were estimated to have experienced the endpoint overall.
Predictors of the endpoint included any cardiovascular event
and lower eGFR or CD4 count [54].
The prevalence of CKD deﬁned by eGFR and/or proteinuria
among cART-naïve patientswas 6.2% in a recent study [55],most-
ly accounted for by the isolated proteinuria CKD criterion, being
only 0.5% due to eGFR <60 mL/min/1.73 m2 [55].
The prevalence of CKD in the general population has been re-
ported to be close to 10%, as exempliﬁed by the Spanish EPIRCE
study [56]. Some studies show a lower CKD prevalence in HIV
patients than in the general population. However, at least
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three reasons may explain this apparent contradiction: (i) mean
prevalence rates in the general population are mainly driven by
the elderly, who are generally not well represented in HIV co-
horts; (ii) SCr-based equations may overestimate eGFR in HIV pa-
tients with decreased muscle mass; and (iii) the very sensitive
urinary albuminuria/creatinine ratio (uACR) >30 mg/g criterion
was used in general population studies, following KDIGO CKD
diagnostic criteria [57], whereas albuminuria was not considered
for CKD diagnosis in several HIV cohort studies.
Traditional risk factors for CKD are becoming increasingly
prevalent in HIV-infected populations, including aging, diabetes
mellitus, hypertension, cardiovascular disease, previous AKI and
race/ethnicity [55]. Risk factors for CKD in HIV-persons are there-
fore a combination of traditional and HIV-related factors includ-
ing low CD4 counts, high viral load, intravenous drug use, HCV
co-infection and also cART, mainly tenofovir, indinavir, lopina-
vir/ritonavir, atazanavir/ritonavir and abacavir [44, 47, 48, 58–
60]. In this regard, a quarter of HIV-infected patients are co-in-
fected by HCV and co-infection with HCVmay cause speciﬁc im-
mune complex-mediated kidney disease [61–63]. Multiple
concurrent risk factors for CKD may have a cumulative effect in
HIV-infected individuals [64]. In this regard, diabetic nephropa-
thy and nephroangiosclerosis are becoming important causes
of CKD. In a German renal biopsy study, immune complex-
mediated glomerulonephritis (26.1%), hypertensive (20.3%) and
diabetic nephropathy (20.3%) were the most frequent causes of
CKD in HIV patients and the latter two accounted for over 50%
of cases in more recent years [65], while arterionephrosclerosis
was the most common kidney diagnosis in a post-mortem
American series [7]. Diabetic nephropathy was the cause of
ESRD in 14% of HIV-positive patients in Spain [6]. Indeed, nephro-
pathy was more common in HIV-infected than uninfected
diabetic patients [66], and expression of an HIV transgene aggra-
vated kidney injury in diabetic mice [67].
The increasing prevalence of age-associated nephropathies is
not surprising. On one hand, as HIV patients are living longer,
they are also getting older. In 2010, individuals older than
55 years old comprised ∼20% of the people living with HIV in
the USA. The CDC estimates that by 2015, >50% of individuals in-
fected with HIV in the USAwill be over 50 years old. On the other,
chronicHIV infection is associatedwith accelerated aging despite
apparent viral control, and therefore is associated with early
onset of diseases linked to aging, including CKD [68]. As an ex-
ample, HIV infection is associated with a signiﬁcant increase in
DNAmethylation in brain tissue and blood, as an epigenetic bio-
marker of aging [69].
An HIV-speciﬁc CKD risk model score (D:A:D score) has been
proposed to calculate the long-term risk of developing CKD
using readily available clinical factors [70]. This model includes
both traditional and HIV-related risk factors and could be used
for identifying patients at high risk of CKD, estimating the
increased risk when a new potential nephrotoxic drug is added
to the cART regimen, and thus aiding in decision-making in
daily clinical practice.
The nephrotoxicity of antiretroviral therapy
The introduction of cART completely changed HIV disease pro-
gression and life expectancy. However, some cART drugs require
dose adjustment or are contraindicated in advanced CKD stages.
As an example of a very widely used drug with nephrotoxic po-
tential, tenofovir disoproxil fumarate dose should be adjusted
when baseline creatinine clearance is below 50 mL/min and com-
binations of tenofovir with emtricitabine are not recommended
when creatinine clearance is below 30–50 mL/min, depending
on the speciﬁc combination [71]. In addition, there is increasing
evidence that cART can lead to a wide variety of nephrotoxic ef-
fects, including both AKI and CKD [24, 33, 34]. The potential in-
sidious long-term kidney toxicity of cART leading to CKD
progression is probably underappreciated. The cARTdrugs usual-
ly associated with CKD include indinavir, atazanavir, tenofovir
disoproxil fumarate and lopinavir/ritonavir [33, 72]. Mechanisms
of nephrotoxicity are summarized in Table 2 and risk factors in
Table 3.
AKI related to cART is more frequent in the ﬁrst year of ther-
apy, but severe kidney dysfunction is rare [33]. The incidence of
AKI decreased 10-fold after the ﬁrst 3 months of cART but on
the other side, cART toxicity causes 14%of all AKI episodes occur-
ring at least 3 months after cART initiation [21]. Of note, in that
study, indinavir contributed to 50% of cART-related AKI. The
use of indinavir has decreased dramatically in more developed
countries.
Since HIV patients are frequently exposed tomultiple drug re-
gimens, deleterious interactions can be difﬁcult to deﬁne andAKI
is frequently deﬁned asmultifactorial. Nevertheless, besides AKI
and CKD, cART can cause an array of nephrotoxic effects (sum-
marized in Table 2).
The incidence of advanced-stage CKD associated with cART
toxicity is low, most likely because close monitoring of eGFR in
most cohort allows cART discontinuation as soon as GFR decline
is detected.
Protease inhibitors. Nephrotoxicity due to protease inhibitors (PIs),
mainly indinavir and atazanavir, is related to the formation of
urinary crystals, and development of nephrolithiasis, acute or
chronic interstitial nephritis, crystal-induced nephropathy, AKI
or CKD [20, 21, 32, 34, 73–75].
Although indinavir is now less frequently used in high in-
come countries because of its potential for crystalluria (67%)
and kidney stones (3%), it is still used in resource-limited settings
[34, 74]. Low indinavir solubility in alkaline urine is the primary
cause leading to intratubular crystals and stones. Risk factors
for crystalluria include volume depletion, warm and/or alkaline
urine, low BMI, high drug concentrations and co-administration
with another nephrotoxic drug [76].
Atazanavir has largely replaced indinavir in cART as it has a
better safety proﬁle. However, approximately 7% of atazanavir
is excreted unchanged in urine and due to its poor solubility,
has the potential for crystalline precipitation at physiologic
urine pH: the frequency of lithiasis ranges from 7.3 to 23.7 per
1000 person-years [73, 77]. Ritonavir-boosted atazanavir expos-
ure has also the potential to cause crystalluria and urolithiasis,
and acute, chronic or granulomatous interstitial nephritis [32,
73, 74]. The overall prevalence of symptomatic urolithiasis due
to atazanavir crystals has been estimated at 0.97% [78]. In epi-
demiological studies, exposure to atazanavir was associated
with a higher incidence of renal stones than other PI-based regi-
mens [79]. In medium- and long-term therapy, crystalluria and
nephrolithiasis are commonly associated with high atazanavir
concentrations [80].
Ritonavir toxicity ismost likely a result of drug interactions ra-
ther than a direct kidney effect. Other PIs such as nelﬁnavir, am-
prenavir, saquinavir, ritonavir and darunavir have also been
reported to cause urolithiasis or to crystallize in urine [74].
Nucleoside analogue reverse transcriptase inhibitors (NRTI). Nucleo-
side analogues such as lamivudine, stavudine and didanosine
are excreted in urine and dose adjustment is required in presence
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of decreasedGFR, but direct nephrotoxicity is rare. However, their
chronic use may cause mitochondrial dysfunction leading to
type B lactic acidosis by inhibiting DNA polymerase-γ [81]. This
effect in proximal tubular cells could explain the generalized
proximal tubule dysfunction (Fanconi syndrome) associated
with stavudine and lamivudine [82]. The prevalence and severity
of lactic acidosis related with long-term NRTIs toxicity can in-
crease in the presence of coexistent hepatocellular injury and re-
duced lactate metabolism, which can be more frequent in HIV
patients because of co-infections or hepatotoxicity [81].
Nucleotide reverse transcriptase inhibitors (NtRTI). Tenofovir, adefo-
vir and cidofovir are NtRTI capable of inducing renal tubular in-
jury. Tenofovir is usually used as disoproxil fumarate and we
will discuss this formulation in this section, only brieﬂymention-
ing the potential for lower nephrotoxicity with a novel formula-
tion, tenofovir alafenamide. The most common nephrotoxic
effect is tenofovir-induced proximal tubular cell damage. Tenofo-
vir is a ﬁrst-line treatment of HIV infection and is currently used
in approximately half of all cART regimens [33, 34]. Although
large prospective trials support the general renal safety of tenofo-
vir disoproxil fumarate [83], its safety proﬁle is still debated, since
cases of AKI, proximal tubular dysfunction and CKD have been
frequently reported when using tenofovir disoproxil fumarate
in clinical practice settings [84]. Tenofovir is excreted unchanged
in the urine and it is cleared bya combination of glomerularﬁltra-
tion and proximal tubular secretion. Active transport is required
for its uptake through basolateral human organic ion transport-
er-1 and for secretion to the tubular lumen through the apical
transporter MRP4 (multidrug resistance-associated protein 4)
[85]. Dysfunction of efﬂux transporters leads to drug accumula-
tion into the proximal tubular cells resulting inmitochondrial in-
jury [86] by a mechanism distinct from NRTIs, as it does not
inhibit DNA polymerase-γ [87]. In recent case series inhibition
of basolateral uptake of tenofovir seemed to protect against tubu-
lar injury [88].
Tenofovir disoproxil fumarate-induced AKI has been reported
in 0.7–10% of patients and subclinical proximal tubular dysfunc-
tion developed in 22–81% of cases [89, 90]. Tubular toxicity was
associated with higher tenofovir plasma concentrations [91]
and with cumulative exposure to atazanavir and tenofovir [92].
Evidence of tenofovir-induced kidney tubular dysfunction
includes Fanconi syndrome, increased excretion of tubular pro-
teins, hyperphosphaturia/hypophosphataemia, glycosuria,
metabolic acidosis and hypokalaemia [93]. Biopsy-proven AKI
cases revealed toxic acute tubular necrosis, with distinctive
proximal tubular eosinophilic inclusions representing giant
mitochondria visible by light microscopy and mitochondrial en-
largement, depletion and dysmorphic changes by electron
Table 2. Manifestations of antiretroviral toxicity [10, 13, 33, 34, 73]
Antiretroviral group Kidney damage mechanism Kidney manifestations
NRTI
Abacavir
Didanosine
Lamivudine
Stavudine
Zidovudine
Inhibition of mitochondrial DNA polymerase; oxidative
phosphorylation and endogenous nucleotide kinases
AKI, AIN (case report)
Fanconi or Fanconi-like syndrome
Type B lactic acidosis
Nephrogenic diabetes insipidus (case reports)
NtRTI
Tenofovir Direct proximal tubular epithelial cells toxicity
Intracellular accumulation
Mitochondrial depletion
Fanconi syndrome
Nephrogenic diabetes insipidus
AKI
Osteomalacia
NNRTI
Efavirenz
Nevirapine
Unknown
Hypersensitivity
Minimal change disease (case report)
Urolithiasis (case report)
AKI (case reports)
Protease inhibitors
Indinavir Intratubular drug precipitation due to poor solubility
(mainly for indinavir, atazanavir)
AKI and CKD
Acute and chronic interstitial nephritis
Nephrolithiasis, asymptomatic crystalluria, crystal
nephropathy
Papillary necrosis
Atazanavir
Nelﬁnavir
Amprenavir
Saquinavir
Lopinavir
Ritonavir
Integrase inhibitors
Raltegravir Skeletal muscle toxicity Rhabdomyolysis and AKI (case reports)
NRTI, nucleoside reverse transcriptase inhibitor; NtRTI, nucleotide reverse transcriptase; NNRTI, non-nucleoside reverse transcriptase inhibitor; AKI, acute kidney injury;
AIN, acute interstitial nephritis; CKD, chronic kidney disease.
Table 3. Predisposing factors for kidney impairment in HIV-infected
patients [18, 70]
Factors associated with kidney impairment
Previous kidney disease
Uncontrolled HIV infection
Time under ART
Older age
Female gender
African background: APOL1 genetic variants
CD4 count <200 cells/mm3
Use of nephrotoxic drugs
HIV, human immunodeﬁciency virus; ART, antiretroviral therapy.
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microscopy [87]. These are also themajor ultrastructural ﬁndings
in tenofovir-induced proximal tubular toxicity [94].
Case reports and more recently epidemiological studies ob-
served that tenofovir disoproxil fumarate decreases eGFR at
rates comparable to diabetic nephropathy [86]. The number of
proximal tubular abnormalities was linearly associated with
eGFR decline since tenofovir initiation [95]. Tenofovir disoproxil
fumarate also causes chronic tubulointerstitial nephritis, which
may account for the lack of reversibility in some individuals [96].
Therefore, concern exists about the long-term safety of tenofovir
disoproxil fumarate, especially in patients with prior kidney ab-
normalities and/or concomitant exposure to nephrotoxic agents.
In a recent retrospective analysis of a prospective French HIV co-
hort of patients starting ART with baseline eGFR >60 mL/min/
1.73 m2, CKD incidence was 9.6 per 1000 patient-years. The inci-
dencewashighest in patients treatedwith boosted PI including te-
nofovir disoproxil fumarate and having a high D:A:D risk score for
CKD, but no impact was observed in patients with a low risk score
[97]. In HIV individuals with normal baseline kidney function, the
association between exposure to cARTs andCKDdevelopment ap-
pears to be cumulative, as shown by the D:A:D study [75]. In ame-
dian follow-up of 7.2 years, the incidence of CKDwas 1.76 per 1000
patient-years and signiﬁcantly increased with each additional
year of exposure to tenofovir disoproxil fumarate, atazanavir/ri-
tonavir and lopinavir/ritonavir. Although the absolute number of
newCKDcaseswasmodest, treatmentwith these cARTs appeared
to result in an increasing and cumulative risk of CKD.
In conclusion, it is prudent to limit exposure to tenofovir dis-
oproxil fumarate in patients with risk factors for nephrotoxicity
and to replace the drug in case of early features of nephrotoxicity.
A new formulation of tenofovir, tenofovir alafenamide, appears
to have reduced kidney toxicity as assessed by serum creatinine
and proteinuria, although hard end-points were not assessed
[98–100]. Indeed, switching to a tenofovir alafenamide-contain-
ing regimen from one containing tenofovir disoproxil fumarate
led to higher eGFR and improved bone mineral density [101]. Te-
nofovir alafenamide favours drug-uptake into immune cells at
low plasma concentrations, and not being a substrate for renal
organic anion transporters, does not accumulate in proximal
tubular cells. Initial results showed slight declines in eGFR and
small increase in proximal tubular dysfunction markers. An on-
going open-label study is evaluating the safety of tenofovir alafe-
namide in patients with creatinine clearance between 30 and 69
mL/min. However, whether tenofovir alafenamide may lead to
nephrotoxicity under speciﬁc circumstances is unknown; there
is no ‘real-world’ experience, which is where tenofovir disoproxil
fumarate nephrotoxicity became apparent, and tenofovir alafena-
mide renal safety in patients with CKD has not been addressed in
randomized controlled trials (RCTs) [102]. In this regard, a recent
RCT comparing the two tenofovir formulations did not ﬁnd any
case of proximal tubular dysfunction with either drug [103].
Other factors associated to kidney disease in the
HIV-infected population
Increased survival of HIV patients under cART has led to complex
interactions of HIV infection with prevalent chronic diseases of
the developed world. Some of these prevalent diseases may
lead to kidney disease. Despite a progressive decrease in the
rate of HIV-speciﬁc kidney diseases with widespread use of
cART, the incidence of CKD [5, 10, 18, 41] and the geographical dif-
ferences appear to remain stable, pointing to the role of other en-
vironmental factors or genetic susceptibility in the pathogenesis
of the disease. Diabetes, metabolic syndrome, hypertension and
atherosclerosis may synergize with HIV infection or cART to ac-
celerate the loss of kidney function, leading to CKD presenting
as decreased eGFR, increased urinary protein excretion or other
abnormal urinary ﬁndings.
Therefore, it remains challenging to distinguish cART-related
nephrotoxicity from direct effects of HIV or non-HIV-related kid-
ney diseases.
Monitoring kidney dysfunction
In general, kidney function in HIV-infected patients declines
slowly, being clinically unapparent. Therefore, a baseline
Table 4. Recommended approach to kidney injury screening in HIV-infected patients [104, 105]
Approach to kidney screening Abnormality
Actionsa
twice yearly in stable patients
Blood pressure measurement
Glomerular ﬁltration rate
Serum creatinine based eGFR (CKD-EPI equation)
Serum cystatin C based eGFR (CKD-EPI equation)
Glomerular injury
uACR
uPCR
uAPR
Urinary sediment (check also for crystals!)
Proximal tubulopathy
Urine dipstick
Glycosuria
FePi
FeUrate
>140/90 mmHg
<60 mL/min/1.73 m2 or rapid
decrease
>30 mg/g
>150 mg/g
>0.4
>0.4
Crystalluria
Hematuria
Abnormal
Present
>10%
>20%
Revise therapy
Search cause, including nephrotoxicity
Nephrology referral
Change to quarterly evaluation
Search for kidney disease (consider biopsy)
Search for glomerular disease
Consider tubulopathy, search for speciﬁc protein lost in urine
Search for cART toxicity
Search for glomerular disease
If proteins: quantify uACR/uPCR
If blood: sediment
If leukocytes: sediment, culture
Check for Diabetes Mellitus or cART toxicity
Search for cART toxicity
Search for cART toxicity
HIV, human immunodeﬁciency virus; eGFR, estimated glomerular ﬁltration rate; uPCR, urinary protein creatinine ratio; uACR, urinary albumin creatinine ratio; uAPR,
urinary albumin protein ratio; FePi, fractional excretion of phosphate; FeUrate, fractional excretion of urate; cART, combined antiretroviral therapy.
aValues should be conﬁrmed.
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assessment of glomerular and tubular function should be made
at the time of diagnosis and on initiation or change of cART.
Regular screening for nephrotoxicity should be performed at
least yearly in stable patients using the same eGFR estimation
method to identify changes over time. CKD or at-risk patients
must be monitored more frequently. Different guidelines have
been proposed recently [104, 105]. Our recommended approach
is shown in Table 4.
SCr and eGFR based on SCr must be interpreted with care in
HIV patients. Despite standardization of SCr assays, GFR estima-
tion by the SCr-based MDRD or CKD-EPI equations is still fairly
imprecise, especially in patients with muscle mass different
from expected for sex and age. HIV-infected patients often pre-
sent with muscle wasting, which can lower SCr and falsely sug-
gest the presence of normal kidney function [106]. Cystatin C is
a new ﬁltration biomarker generated at a fairly constant rate in
nucleated cells, freely ﬁltered in the glomerulus and totally ex-
creted. The CKD-EPI group has developed equations based on Cy-
statin C and on its combination with SCr, which appear more
suitable for estimating GFR in this population [107]. Nephrotox-
icity is mainly presented as tubular injury, therefore to assess
tubular function urinary albumin/creatinine (uACR) and urinary
protein/creatinine (uPCR) ratios allows the calculation of the
uACR /uPCR ratio (uAPR). A uAPR <0.4 suggests the excretion of
low molecular weight proteins that arise from tubular failure to
reabsorb ﬁltered low molecular weight proteins such as light
chains [108]. A uAPR <0.4 in association with increased uric
acid and phosphorus excretion fractions appears to be highly
sensitive and speciﬁc for proximal tubular injury. The presence
of crystalluria may also point to potential nephrotoxicity, al-
though the value of crystalluria to predict development of CKD
has not been tested.
Implementation of risk score models as part of routine care
would allow graded consideration of the safest drugswhen initiat-
ing and switching antiretrovirals, as well as identifying indivi-
duals who require more intensive kidney monitoring [70]. The
D:A:D risk score helps to individualize the risk for cART-nephro-
toxicity andCKD development. Nevertheless, it still lacks accurate
biomarkers of early tubular toxicity associated to the HIV-speciﬁc
risk score for CKD to be applied at the point of care. Fractional ex-
cretion of phosphate showed a good performance as an early
marker of tubular dysfunction, and should be incorporated as a
tool of CKD prediction. Urinary phosphatewastingwas a sensitive
marker for tenofovir-induced proximal tubular dysfunction and
was associated with unrecognized and permanent kidney func-
tion decline [109]. However, prediction risk models are not yet
broadly implemented in routine clinical practice, although imple-
mentation has the potential to increase the safety of ART [110].
If there is suspicion of cART-induced proximal tubular injury,
the following tests should be performed if not already available in
the setting of routine monitoring: glycosuria and blood glucose,
uAPR, and uric acid and phosphorus excretion fractions.
Therapeutic approach to the patient with CKD and HIV
infection
Standard therapies for CKD applied to the general population are
recommended to prevent CKD progression in HIV patients, in-
cluding appropriate management of cardiovascular risk factors
like albuminuria, diabetes, dyslipidemia and blood pressure con-
trol. Avoiding nephrotoxic agents is also recommended to pre-
serve kidney function [104, 105].
Nephrologist referral is recommended when eGFR decreases
by more than 25% from baseline, to less than 60 mL/min/
1.73 m2 or if there is evidence of glomerular or tubular damage
[105]. In case of CKD progression to ESRD, HIV patients on renal
replacement therapies have similar survival rates to other kidney
disease patients and the choice of haemodialysis or peritoneal
dialysis does not appear to impact survival. Selected ESRD HIV-
infected patients can be recipients of kidney transplant with
good graft survival if eligibility criteria are met [111].
Conclusions
In summary, HIV infectionmay promote kidney injury due to dir-
ect infection of kidney cells or because of immune response to
viral antigens or opportunistic agents. Additional risk for kidney
injury results from cART, therapy for other infections and the
concomitant presence of other chronic diseases associated with
kidney injury. An improved understanding of the pathogenesis of
these complex interactions may allow the development of novel
tools tomonitor kidney health, allowing early diagnosis of kidney
dysfunction. As therapy for HIV continues to evolve, nephrolo-
gists must keep abreast of current developments in order to pro-
vide the best care to this population.
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